Bio-Techne Corp (TECH)
OvervaluedFundamental
57
Price
$72.39
Market Cap
$11.36B
Part 1 · What the company is worth
Overview
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$1.22B
Trailing 12 months (through 6/30/2026)
Net Income
$182M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$263M
Total Equity
$2.11B
Total Liabilities
$479M
Current Ratio
4.55
Interest Coverage
26.16
Debt/EBITDA
0.83
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$42.78
Current Price
$72.39
Margin of Safety
-69.2%
Fair Value Range
$27.81 - $57.76
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
62.47
ROE
8.6%
P/B Ratio
5.39
P/FCF
43.17
Gross Margin
65.8%
ROIC
8.2%
Profitability Radar
Value Creation (Economic Moat)
ROIC
8.2%
WACC
11.4%
ROIC − WACC
-3.2 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (17)
- Price CAGR 10.93%
- ROIC 8.2%
- Gross Margin 65.8%
- Debt/Equity ratio
- Operating Margin 20.7%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 8.9%
- Revenue Growth 5Y 5.5%
- Earnings Quality (OCF/NI) 1.61
- Share Dilution -1.7%
- Net Margin Trend 15.0% vs 6.0%
- Piotroski F-Score 8/9
Failed (10)
- EPS shows upward trend
- EPS CAGR -5.01%
- P/FCF 43.17
- P/B Ratio 5.39
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Analyst Consensus 32% Buy
- Earnings Surprise avg -0.8%
- PEG Ratio 10.47
Unavailable (1)
- Dividend Payout NaN%
Piotroski F-Score
Strong financial health
Earnings Quality
High quality: earnings backed by cash
Share Dilution
Buying back shares. Shareholder friendly
Institutional Holdings
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Kim Kelderman | CEO, President & Director | 57 |
| Mr. James T. Hippel CPA | Executive VP of Finance & CFO | 54 |
| Mr. Shane V. Bohnen | Senior VP, General Counsel, Corporate Secretary & Chief Sustainability Officer | 50 |
| Mr. William A. Geist | President of Protein Sciences Segment | 56 |
| Dr. Gary J. Latham Ph.D. | VP & CTO | - |
| Mr. David Clair C.F.A. | Vice President of Investor Relations | - |
| Mr. Martin Wirtz | Senior Vice President of Strategy & Corporate Development | - |
| Ms. Cheryl Bethune | Senior VP & Chief Human Resources Officer | - |
| Mr. Luca Cicchetti | Managing Director | - |
| Mr. Steven C. Crouse | President of Diagnostics & Spatial Biology Segment | 52 |
Audit Risk
7
Board Risk
1
Compensation Risk
10
Shareholder Rights Risk
1
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Documents
- View document
Annual Report (10-K)
A yearly overview of the business, its financial results, and the risks it faces.
Filed on 2026-08-24
- View document
Quarterly Report (10-Q)
A snapshot of financial performance for the most recent three-month period.
Filed on 2026-05-06
- View document
Current Report (8-K)
An announcement of a major event, such as a leadership change or big news.
Filed on 2026-09-23
via SEC EDGAR
Income History
via SEC EDGAR
Latest News
Recent headlines for TECH, sourced from Markets Gazette.
- 6/15/2026POSITIVEActivist Investor Ananym Urges Bio-Techne to Consider Selling
Activist investor Ananym Capital Management has acquired a significant stake in Bio-Techne Corp., signaling a potential shift in the company's strategic direction. Ananym is actively urging the Bio-Techne board to initiate a comprehensive strategic review, with a primary focus on exploring a potential sale of the company. This development could lead to a substantial premium for shareholders if a sale materializes, as activist campaigns often aim to unlock shareholder value through such actions. Investors will be closely watching Bio-Techne's response and any subsequent strategic decisions.
- 3/13/2026NEGATIVEIs Bio-Techne Stock a Buy, Sell, or Hold After a Wealth Manager Dumps Its Entire Stake?
A significant wealth management firm has divested its entire stake in Bio-Techne Corporation, a developer of life sciences reagents and diagnostic solutions. While the specific reasons for the liquidation were not disclosed, the complete exit by a major investor raises concerns about potential headwinds or a reassessment of the company's future growth prospects. Investors will be closely watching for any further commentary from the firm or Bio-Techne management to understand the underlying drivers of this substantial sell-off, which could impact short-term sentiment and stock performance.
via Markets Gazette